Melphalan high dose chemotherapy for patients chemotherapy with autologous stem cell transplantation. Medical search. Frequent questions

OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
Here we present an analysis of SPM incidence and profile the SPM type to determine the impact of autologous stem cell transplantation (ASCT) and lenalidomide exposure in 4358 patients treated on study. (nyu.edu)
The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
Importantly, pre-ASCT M-MDSCs more strongly inhibited the in vitro cytotoxic effect of melphalan compared with pre-ASCT E-MDSCs. (biomedcentral.com)
Finally, blockade of CSF1R substantially recovered the melphalan-induced cytotoxicity reduced by pre-ASCT M-MDSCs. (biomedcentral.com)
Our data demonstrate that pre-ASCT M-MDSCs are correlated with poor clinical outcomes after ASCT through reduced cytotoxicity of melphalan. (biomedcentral.com)
We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
6 , 9 The demonstrated efficacy, lack of myelosuppression, and overall tolerability of thalidomide provide a strong rationale for its incorporation in standard induction regimens for patients presenting with NDMM who may be eligible for ASCT. (haematologica.org)
Combination vincristine, doxorubicin, and dexamethasone (VAD) is considered a standard infusional induction therapy for younger MM patients prior to HDT and ASCT. (haematologica.org)
The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. (nature.com)
We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. (nature.com)
By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. (nature.com)
Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation ( P =0.009). (nature.com)
Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ ( P =0.007). (nature.com)
During the COVID-19 outbreak, planned autologous stem cell transplant (ASCT) for patients may be postponed to a more suitable time. (mpeurope.org)
High-dose therapy (usually high-dose melphalan), and the ASCT procedure itself, weaken the immune system and potentially make myeloma and AL amyloidosis patients more susceptible and less able to fight infections like COVID-19. (mpeurope.org)
Patients who undergo ASCT also need to regularly attend hospital appointments for monitoring, increasing the risk of COVID-19 transmission through social interactions. (mpeurope.org)
The decision about whether an ASCT will proceed during this time can only be made between a patient and their doctor. (mpeurope.org)
The ability of a hospital to effectively isolate patients undergoing ASCT. (mpeurope.org)
As with all treatment decisions during the COVID-19 outbreak, the benefits and risks of a patient undergoing ASCT must be balanced. (mpeurope.org)
In most European countries, ASCT is taking place only where it is considered the best and most appropriate course of action for a patient. (mpeurope.org)
If patients have any specific questions or concerns about their ASCT, they should talk directly to their doctor, nurse or healthcare team. (mpeurope.org)
Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). (haematologica.org)
Across 450 clinical samples and six disease stages, expression levels of genes in the BER pathway were found to be highly upregulated during the development of MM. In a separate cohort of 559 patients with MM treated with ASCT, expression of BER pathway members MPG and PARP3 was positively associated with overall survival (OS) while expression of PARP1, POLD1, and POLD2 was negatively associated with OS. (haematologica.org)
In a validation cohort of 356 patients with MM treated with ASCT, PARP1 and POLD2 findings were replicated. (haematologica.org)
In patients with MM who never received ASCT (n=319), PARP1 and POLD2 were not associated with OS, suggesting that the prognostic effect of these genes may be treatment-dependent. (haematologica.org)
The negative prognosis associated with PARP1 and POLD2 expression along with the apparent melphalan-sensitizing effect of PARP inhibition may suggest this pathway as a potential biomarker in patients with MM in the setting of ASCT. (haematologica.org)
1 Despite significant therapeutic advances for MM, autologous stem cell transplant (ASCT) following high-dose, single-agent melphalan conditioning remains a cornerstone of therapy. (haematologica.org)
1 Although ASCT provides significant benefits to some patients with MM, it is not curative and is associated with significant heterogeneity in clinical benefit. (haematologica.org)
2 The primary driver of response to ASCT is the depth of anti-myeloma activity of melphalan. (haematologica.org)
3 Patients achieving deeper remission receive the greatest duration of clinical benefit following ASCT. (haematologica.org)
4 While studies have historically noted an increased overall survival (OS) in patients with MM who receive ASCT, the recent DETERMINATION trial demonstrates only progression-free survival (PFS) benefit in patients with MM randomized to receive triplet therapy (lenalidomide, bortezomib, and dexamethasone followed by lenalidomide maintenance) with or without ASCT. (haematologica.org)
5 This data proves an urgent need to identify biomarkers of de novo response and resistance to ASCT in order to improve patient selection for this therapeutic modality. (haematologica.org)
The engineered cord endothelial cell (E-CEL) product AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT). (targetedonc.com)

Conditioning regimens consisted of high-dose melphalan (MEL) with or without total body irradiation (TX1 = 35) and MEL as the first preparative regim. (shengsci.com)
These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM. (elsevierpure.com)
One hundred patients (receiving 123 conditioning regimens) were included in the analysis. (nature.com)
17. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. (whocc.org.cn)
Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on positron-emission tomography (PET) scanning throughout the various regimens. (medscape.com)
Regimens that combine chemotherapy and radiation therapy (RT) have replaced RT alone for treatment of early-stage, favorable disease. (medscape.com)
Our patients were treated fairly uniformly at the time of this study: vincristine, doxorubicin, and dexamethasone and oral melphalan and prednisone regimens were mostly used as induction therapy (according to patient age and eligibility for high-dose therapy), with thalidomide-based protocols as second-line therapy and bortezomib-based protocols as third- or next-line therapy. (jcancer.org)

Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma. (haematologica.org)
A trend toward an overall survival advantage for cyclophosphamide-thalidomide-dexamethasone over cyclophosphamide-vincristine-doxorubicin-dexamethasone was also observed in a subgroup of patients with favorable interphase fluorescence in situ hybridization. (haematologica.org)
Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
Cardiac complications have been described in HSCT with the majority of reported cardiac complications during HSCT attributed to the use of high-dose cyclophosphamide [30]. (slideshare.net)
These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
All patients received multi-agent induction chemotherapy for 6 cycles, including an initial 2 cycles of high-dose cyclophosphamide plus topotecan followed by blood stem cell collection. (oncologynurseadvisor.com)
After completion of induction chemotherapy, patients were randomly assigned to receive a single autologous HCT with CEM (carboplatin, etoposide, melphalan) chemotherapy or a double/tandem autologous HCT with thiotepa plus cyclophosphamide prior to the first transplantation followed by a modified CEM regimen prior to the second. (oncologynurseadvisor.com)
She also noted that it is now unclear which is the best consolidation regimen for this patient population, as randomized studies have evaluated different combinations of busulfan, melphalan, thiotepa, cyclophosphamide, and other chemotherapy agents. (oncologynurseadvisor.com)
The patient was treated with chemotherapeutic drugs (cyclophosphamide, vincristine, therarubicin, and cisplatin), irradiation of the abdominal cavity, and surgical resection of the adrenal gland, followed by autologous peripheral blood stem cell transplantation (PBSCT). (biomedcentral.com)
High-dose cyclophosphamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) was then used to mobilize stem cells prior to peripheral blood stem cell (PBSC) collection. (cancertreatmenttoday.org)

After 4 cycles of chemotherapy with topotecan and etoposide, 131 I-MIBG treatment was performed at a dose of 18 mCi/kg. (biomedcentral.com)
After stem cell collection, EDAP (etoposide, dexamethasone, cytarabine, cisplatin) was given to enhance reduction of tumor cells prior to high-dose therapy (melphalan 200 mg/m²) and autologous transplant. (cancertreatmenttoday.org)

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
High-dose melphalan followed by autologous peripheral blood stem cell transplantation may also be used. (merckmanuals.com)
In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)

Options include chemotherapy using bortezomib, autologous stem cell transplantation, immunomodulatory drugs, and kidney transplant. (wikipedia.org)
A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. (biomedcentral.com)
Methods: Myeloma XI is a large, phase III randomised trial in-which lenalidomide was used at induction and maintenance, in transplant eligible (TE) and non-eligible (TNE) newly diagnosed patients (NCT01554852). (nyu.edu)
Dr. Garfall of the University of Pennsylvania describes how CAR T cell therapy works and how the first target of CD19 was used in combination with autologous stem cell transplant. (healthtree.org)
Used for patients who had already relapsed after transplant in a clinical trial of 10 patients, he shares the mixed results to date with one del 17 patient that never achieved complete response (CR) in the first transplant, achieving it in the second transplant with the addition of CAR T cell therapy. (healthtree.org)
05). Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before transplant. (slideshare.net)
Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
In the single autologous HCT arm, 129 of the 179 patients were subsequently given dinutuximab, an anti-GD2 monoclonal antibody, plus cytokine immunotherapy after single transplant consolidation therapy. (oncologynurseadvisor.com)
Similarly, 121 of the 176 patients in the other arm received this immunotherapy after double transplant consolidation therapy. (oncologynurseadvisor.com)
Transplant Cell Ther 2021. (harvard.edu)
Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
Only patients who were not treated with autologous or allogeneic hematopoietic stem cell transplant were included. (jcancer.org)
followed by autologous HCT, which is when the cells used in the transplant are the patient's own. (curetoday.com)
This is the first study that suggests acupuncture being a non-drug therapy that reduces symptoms and use of pain medications in bone marrow transplant patients," said Deng. (curetoday.com)
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant. (mdanderson.org)
Few patients in this category qualify to proceed to an allogeneic stem cell transplant. (mdanderson.org)
In the phase 1 dose-escalation study (NCT03925935), investigators enrolled patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma undergoing their first hematopoietic stem cell transplant who were eligible for HDT-AHCT and had an ECOG performance status of 0 to 1. (targetedonc.com)
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. (uchicago.edu)
One needs to differentiate between tandem transplants, a planned sequence of two high dose treatments with HSCT salvage, and a second transplant, an approach of consolidating the first autologous HSCT with another HSCT ONLY if the first one appears partially effective. (cancertreatmenttoday.org)
A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
Stem cells are collected once before the initial transplant and half are used for each procedure. (cancertreatmenttoday.org)
On the other hand, for patients who have not responded completely, NCCN recommends second transplant. (cancertreatmenttoday.org)
The second course of high-dose therapy and transplant was performed 3 to 6 months later. (cancertreatmenttoday.org)
In addition, it has yet to be determined which patients benefit most from a tandem transplant. (cancertreatmenttoday.org)
The issue of allogeneic after autologous transplant is reviewed under a separate heading. (cancertreatmenttoday.org)
Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
Radiation Therapy for Young Children Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant for Primary Brain Tumors. (ucdenver.edu)

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
Biology of Blood and Marrow Transplantation , 25 (7), 1312-1319. (elsevierpure.com)
Interim results of the phase 1b/2 AB-205-001 trial (NCT03925935), presented during the 47th Annual Meeting of The European Society for Blood and Marrow Transplantation, showed AB-205 to be particularly effective in eliminating oral/ gastrointestinal (GI) severe regimen-related toxicities (SRRT) for these patients. (targetedonc.com)

It occurs in 10-15% of patients with full-blown multiple myeloma but can also be seen when the affected patient has less than 10% bone marrow plasma cells, the quantity typically required to make a diagnosis of myeloma. (askhematologist.com)
Figure 8‐2 Acute leukemia can be considered "naturally metastatic" in that the neoplasm arises within the white blood cell progenitors produced in the bone marrow. (pocketdentistry.com)
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
Atkinson K, Meyers J, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. (nature.com)
Infection with varicella-zoster virus after marrow transplantation. (nature.com)
Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. (nature.com)
Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. (nature.com)
Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
usually normocytic and normochromic related both to the replacement of normal marrow by expanding tumour cells and to the inhibition of haematopoiesis by factors made by the tumour. (sunzek.com)
Based on the presence of at least 10% clonal bone marrow plasma cells and monoclonal protein in serum or urine. (sunzek.com)
In patients with true nonsecretory myeloma, the diagnosis is based on 30% monoclonal bone marrow plasma cells or a biopsy proven plasmcytoma. (sunzek.com)
Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
Myeloma is a B-cell malignancy that is characterised by the monoclonal expansion and accumulation of abnormal plasma cells within the bone marrow. (bmj.com)
Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
Multiple myeloma (MM) is an incurable plasma cell malignancy of the bone marrow. (snmjournals.org)
Multiple myeloma (MM) is an incurable malignancy characterized by clonal proliferation of plasma cells in the bone marrow microenvironment. (snmjournals.org)
There is no end organ damage in MGUS or in a more progressed condition called smoldering MM. Accordingly, MGUS and smoldering MM are usually not treated, but there are investigational chemoprevention trials attempting to halt the progression to symptomatic MM. In smoldering MM, bone marrow biopsy shows a 10%-60% diffuse infiltration of plasma cells, and the infiltration is less than 10% in MGUS. (snmjournals.org)
Although MM can arise de novo, it usually progresses in a stepwise fashion from MGUS or smoldering MM. If marrow infiltration with plasma cells exceeds 60%, or if end organ damage is present, the patient is diagnosed with active MM ( 1 , 2 ). (snmjournals.org)
Extramedullary hematopoiesis (EMH) is likely the result of abnormal trafficking of hematopoietic stem cells (HSC) from the bone marrow to organs such as the spleen, liver, and lung, causing organomegaly and sometimes organ dysfunction. (cancernetwork.com)

Clinical scientists continue to observe superior survival of patients treated with combined chemotherapy and radiation approaches, yet the mechanisms behind this synergistic therapeutic approach are not fully understood. (mdanderson.org)
Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
Thalomid was also associated with higher event-free survival at five years (56% versus 43%), but the overall survival rate was no different at 65% a piece. (pharmatimes.com)
Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
Background: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. (elsevierpure.com)
Conclusions: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (elsevierpure.com)
The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
In vivo development and survival of NK cells require cytokines ( 6 - 8 ). (frontiersin.org)
Results showed that 3-year event-free survival was 48.4% ± 3.8% with single autologous HCT compared with 61.4% ± 3.7% with tandem autologous HCT ( P =.0081). (oncologynurseadvisor.com)
The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
Three-year follow-up data from the Phase II ZUMA-2 trial showed a long-term survival benefit and low disease relapse potential with one infusion of the anti-CD19 chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (KTE-X19) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). (mdanderson.org)
BTK inhibitors have greatly improved outcomes in R/R MCL, yet patients who have subsequent disease progression are likely to have poor outcomes, with median overall survival of just six to 10 months. (mdanderson.org)
Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
The final analysis of the landmark French IFM-94 trial demonstrated that double transplantation led to improved survival compared with single transplantation in patients with previously untreated myeloma. (cancertreatmenttoday.org)
Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
In recent years, with a combination of autologous stem-cell transplantation and modern chemotherapy, the 10-y survival of patients presenting at an age less than 60 y is approximately 30% ( 1 , 2 ). (snmjournals.org)
Additionally, ruxolitinib is the only agent that has demonstrated a survival benefit in patients with MF. (cancernetwork.com)
The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)

3.2 mg/kg/day busulfan on days -5 to -3 and 140 mg/m 2 /day melphalan on day -2) in patients with multiple myeloma (MM) following bortezomib-based induction chemotherapy. (elsevierpure.com)

The pursuit of technical advancement continues as investigators seek novel ways to improve patient outcomes. (mdanderson.org)
As multi-modality approaches to cancer continue to improve patient outcomes, limiting treatment related morbidity is essential. (mdanderson.org)
Her clinical and research interests lie in improving the outcomes of patients with lymphoma. (mdanderson.org)
Dr. Pinnix's ultimate aspiration is to advance the clinical outcomes of patients afflicted with Hodgkin's and Non-Hodgkin's lymphoma via the minimization of normal tissue toxicity related to radiotherapy. (mdanderson.org)
Because pilot studies of tandem autologous HCT demonstrated tolerable toxicity and potential efficacy and because prior trials have demonstrated that dose intensification improves outcomes, researchers decided to explore tandem transplantation in patients with high-risk neuroblastoma. (oncologynurseadvisor.com)
The Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and the PROMIS Cognitive Function Short Form were used as research tools. (bmj.com)
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. (uchicago.edu)
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
In an effort to improve long-term outcomes, some myeloma patients seek to use dietary supplements, mostly for palliative purposes. (bmj.com)

The high‐dose induction chemotherapy regimen that will be used to treat this patient is profoundly myelosuppressive, and typically causes severe ulcerative oral mucositis for at least two weeks duration. (pocketdentistry.com)
15. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. (whocc.org.cn)
However, the regimen we use for high-risk neuroblastoma is also the most aggressive and toxic regimen we give to children with cancer. (oncologynurseadvisor.com)
The highest dose of 20 × 106 E-CEL/kg demonstrated robust effect in eliminating oral/GI severe regimen-related toxicities. (targetedonc.com)
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. (uchicago.edu)

Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). (biomedcentral.com)
Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. (shengsci.com)
Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression. (biomedcentral.com)
Many culturing strategies are based on the addition of feeder or accessory cells, which need to be removed prior to the clinical application of the final NK cell product. (frontiersin.org)
Objectives To classify subgroups of cancer-related symptoms in patients with multiple myeloma (MM) during treatment and examine between-group differences in demographic and clinical characteristics in addition to functional status. (bmj.com)
The identification of patients with high symptom burden management should focus on the assessment of demographic and clinical characteristics, in addition to functional status. (bmj.com)
This study assessed between-group differences in the demographic and clinical characteristics and functional status of patients with MM. (bmj.com)
Patient clinical characteristics did not include the evaluation of treatment response. (bmj.com)
We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Below is a Question and Answer (Q&A) on how treatment, hospital appointments and clinical trials may be affected for patients. (mpeurope.org)
Patients and clinical evaluators did not know which patients were assigned to either group. (curetoday.com)
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting . (mdanderson.org)
The next most common clinical problem in patients with myeloma is susceptibility to bacterial infections. (sunzek.com)
However, melphalan efficacy is variable in the clinical population, especially in relapsed and refractory MM, and is also implicated in various toxicities, including severe mucositis and myelosuppression. (snmjournals.org)
There was an increased incidence of venous and arterial thrombotic events in patients with multiple myeloma who received lenalidomide in combination with dexamethasone compared with dexamethasone alone in clinical trials. (pdr.net)

1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)

Last year, Celgene was forced to discontinue a trial of a thalidomide derivative - Revlimid (lenalidomide) - in multiple myeloma patients after patients developed blood clots. (pharmatimes.com)
We'd like to thank today's episode sponsor Takeda Oncology for their support of Myeloma Crowd Radio and myeloma patients as a whole. (healthtree.org)
14. Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents. (whocc.org.cn)
Based on our earlier research into the main characteristics and risk factors for infections in hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients. (jcancer.org)
As far as we know, this index represents the first attempt to create such an instrument for predicting the occurrence of infections in myeloma patients. (jcancer.org)
We tried to create the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients and help identify patients who have a higher risk for developing infections. (jcancer.org)

Patients with residual disease after neoadjuvant chemotherapy (NAC) face an increased risk of relapse and death. (bvsalud.org)
Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
It is encouraging to see this therapy induced durable long-term responses and a low relapse rate for these patients. (mdanderson.org)
The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. (biomedcentral.com)
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. (bmj.com)
Equivocal end-of-therapy imaging findings do not predict a higher risk of local relapse after definitive radiotherapy in pediatric Ewing sarcoma and rhabdomyosarcoma. (ucdenver.edu)

Figure 8‐1 Peripheral blood smear from a patient with newly diagnosed acute myelogenous leukemia in blast crisis. (pocketdentistry.com)
B) Gingival leukemic infiltrate in newly diagnosed acute myelogenous leukemia patient. (pocketdentistry.com)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)

Although there was evidence of a response to CTD (M-protein 34 g/L), bortezomib and dexamethasone treatment was initiated as an alternative, but this was discontinued after three cycles due to progressive disease (M-protein 49 g/L). The patient was then treated with lenalidomide and dexamethasone with the aim of reducing disease burden prior to high-dose therapy and autologous stem cell transplantation. (bmj.com)
This tumor-induced diffuse bone loss compounds the treatment-induced bone loss from frequent use of high-dose glucocorticoid medications (typically dexamethasone), leading to severe osteoporosis. (snmjournals.org)

Patients treated with isatuximab-RVd (six cycles) had lower numbers of collected stem cells compared to those receiving RVd (six cycles) induction (8.8 × 10 6 /kg bw versus 9.7 × 10 6 /kg bw, p = 0.801), without experiencing significant delays in LP or increased numbers of LP sessions in a multivariable logistic regression analysis. (biomedcentral.com)
This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
The SPM incidence was higher in patients who received lenalidomide at induction and maintenance (double exposure), when compared to those treated with lenalidomide at one time point (single exposure). (nyu.edu)
Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
However, direct injection of IL-2 has been shown to be accompanied by severe side effects, such as vascular leak syndrome, activation-induced cell death, and strong induction of regulatory CD4 pos T cells, which did not occur after IL-15 administration ( 15 , 16 ). (frontiersin.org)

Additional components include staging (solid tumors), age and performance status of the patient, projected efficacy in relation to toxicity, and patient preferences. (pocketdentistry.com)
Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
A subsequent cohort with 41 patients was analyzed in a phase II trial to identify safety and efficacy. (elsevierpure.com)
H publication of preliminary data reporting its efficacy in epatitis E virus (HEV) is a nonenveloped RNA virus such patients ( 12 ). (cdc.gov)

For post-transplantation best response, an 83% rate of VGPR or better (68% CR) was observed. (elsevierpure.com)
Researchers used the MD Anderson Symptom Inventory (MDASI) at baseline, during transplantation and at 15 and 30 days' post-transplantation to evaluate the patients. (curetoday.com)
They determined that true acupuncture did not show significant reductions in overall MDASI core symptom scores and symptom interference scores during transplantation, at 15 days and at 30 days' post-transplantation. (curetoday.com)
Among those who received sham acupuncture, they were more likely to increase pain medication use post-transplantation. (curetoday.com)

Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. (uchicago.edu)

Besides surgery, radiotherapy and chemotherapy, immune activation by direct application of cytokines, antibodies or adoptive cell therapy are promising approaches. (frontiersin.org)

Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. (smw.ch)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
This represents the longest follow-up of CAR T cell therapy in patients with mantle cell lymphoma to date," Wang said. (mdanderson.org)
AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation. (targetedonc.com)
To establish a modern historical control concurrent with study enrollment, a chart review was concurrently conducted of 45 consecutive patients undergoing AHCT for systemic lymphoma. (targetedonc.com)
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. (ucdenver.edu)

He's a member of ASH and ASCO and he's a popular lecture/speaker on an Anti-CD19 CAR T Cell immunotherapy for multiple myeloma. (healthtree.org)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
1 , 7 Consensus guidelines in this difficult-to-treat population are challenging to create given the small numbers of patients and multiple treatment options in this era of burgeoning cellular and immunotherapy. (jnccn.org)

While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. (bmj.com)
Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. (snmjournals.org)

The study of 668 patients with newly-diagnosed multiple myeloma compared treatment with two courses of Celgene's Alkeran (melphalan) to the combination of Alkeran and Celgene's Thalomid brand of thalidomide alongside autologous stem cell transplantation. (pharmatimes.com)
The combination treatment was also associated with higher rates of blood clots and damage to the nerves. (pharmatimes.com)
for example, intense oral and pharyngeal pain induced by a combination of oral mucositis, oropharyngeal candidiasis, salivary gland hypofunction, and xerostomia frequently lead to dysphagia in cancer patients compromising nutritional intake. (pocketdentistry.com)
Later, meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. (nyu.edu)
In a proof of concept in vivo study, we also observed a therapeutic effect of adoptively transferred IL-15 expanded and IL-21 boosted NK cells in combination with image guided high precision radiation therapy using a luciferase-transduced RMS xenograft model. (frontiersin.org)
HCT used in combination with high-dose chemotherapy can offer patients a chance for durable remission. (curetoday.com)
In preclinical models of MM, synergy was observed in anti-tumor activity when poly (ADPribose) polymerase (PARP) inhibitors (olaparib, talazoparib) were used in combination with melphalan. (haematologica.org)

Multiple Myeloma (MM) is an incurable plasma cell malignancy that accounts for 18% of all hematologic malignancies. (haematologica.org)
Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)

We retrospectively analyzed archived paired (pre- and post-NAC) tumor samples from 25 patients with TNBC with residual disease using a targeted 72-gene next-generation sequencing panel. (bvsalud.org)
New therapeutic concepts in anti-tumor therapy aim to modulate the patient's immune system to increase its aggressiveness or targeted effects toward tumor cells. (frontiersin.org)
18 F-FDOPA PET/CT complemented 18 F-FDG PET/CT in imaging melphalan therapy response in preclinical extramedullary MM. 18 F-FDOPA uptake was linked to LAT1 expression and melphalan response, with longitudinal imaging suggesting stabilization of LAT1 levels and melphalan tumor cytotoxicity. (snmjournals.org)

Figure 8‐2 ) may be treated by moderate or high‐dose chemotherapy, with or without hematopoietic stem cell transplantation (HSCT). (pocketdentistry.com)
HSCT‐related oral toxicities are additionally influenced by the degree of genetic disparity between donor and patient. (pocketdentistry.com)

This is especially true in the treatment of young patients with radiation therapy. (mdanderson.org)
As with head and neck cancer patients, factors influencing incidence and severity of oral complications across patients with hematologic disease include extent of oral disease prior to cancer treatment, intensity of cancer therapy, genetically‐governed susceptibility to oral mucosal injury, and patient compliance with health professional Recommendations regarding oral hygiene, diet, smoking cessation, and related variables. (pocketdentistry.com)
A main challenge of NK cell therapy is that it requires a high amount of functional NK cells. (frontiersin.org)
Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
Less than 50% of children with high-risk neuroblastoma will survive following current multi-agent, aggressive therapy. (oncologynurseadvisor.com)
This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment. (curetoday.com)
If confirmed in a larger study, we would have one more therapy that helps those patients through the course of transplantation. (curetoday.com)
All patients had R/R disease after receiving up to five therapies, and all had received previous Bruton's tyrosine kinase (BTK) inhibitor therapy. (mdanderson.org)
The findings support future study of CD19-directed CAR T cell therapy in patients with high-risk MCL in earlier treatment lines. (mdanderson.org)
In general such therapy is of two sorts: systemic chemotherapy to control progression of myeloma, and symptomatic supportive care to prevent serious morbidity from the complications of the disease. (sunzek.com)
Walking with patients through this journey from start to finish, and offering therapy and guidance along the way, is a source of professional and personal satisfaction for me. (rochester.edu)
Iodine-131-metaiodiobenzylguanidine ( 131 I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. (biomedcentral.com)
Based on our findings, we suggest that 131 I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible. (biomedcentral.com)
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
Two hundred thirty-one patients with symptomatic myeloma were enrolled in Total Therapy I between 1990 and 1995 (Barlogie et al. (cancertreatmenttoday.org)
To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy. (bmj.com)
Melphalan therapy induced a statistically significant reduction in lesion avidity and uptake for both 18 F-FDG and 18 F-FDOPA. (snmjournals.org)
Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
Thus, stratification of melphalan-responsive patients in the MM patient population is critical for reducing therapy-induced toxicities. (snmjournals.org)
Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy. (ucdenver.edu)
In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice. (cancernetwork.com)
Hematopoietic stem cell transplantation is the only potentially curative therapy, but it is only an option for select patients. (cancernetwork.com)

Moreover, none of the patients with an EF less than 50% developed cardiac toxicity. (slideshare.net)
High-dose chemoradiotherapy is the major cause of organ toxicity. (slideshare.net)
Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients [33]. (slideshare.net)
0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m 2 (8.2% vs 14.7%, NS). (nature.com)

2019. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. . (cornell.edu)

Stopping treatment altogether, where clinically appropriate to do so (e.g. where a patient is in good remission). (mpeurope.org)
Stable focal osteolytic bone lesions of skull and right humerus in a patient with MM in complete remission for 5 y. (snmjournals.org)
Lateral skull (left) and humeral shaft (right) radiographs of the patient demonstrate multiple focal osteolytic lesions (some with arrows) that will never heal even if patient remains in complete remission for many years. (snmjournals.org)

Invited discussant for this abstract Dominique Valteau-Couanet, MD, PhD, head of the pediatric and adolescent oncology department at Institut Gustave Roussy in France, questioned which patients actually benefit from tandem autologous HCT: patients with localized disease and MYCN amplification? (oncologynurseadvisor.com)
It appears that in patients with poor prognostic features, outcome is not improved with tandem transplants, so additional strategies need to be evaluated in this patient population. (cancertreatmenttoday.org)

Methods: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. (elsevierpure.com)
For the study, researchers enrolled 355 children (median age, approximately 3 years) who were newly diagnosed with high-risk neuroblastoma. (oncologynurseadvisor.com)
Renal impairment occurs in 20 - 40% of patients with newly diagnosed disease, mainly as a result of direct tubular damage from excess protein load, dehydration, hypercalcemia and the use of nephrotoxic medications. (sunzek.com)

The most common type of amyloidosis and used to be called primary amyloidosis results when light chains are produced in excess by clonal or frankly malignant plasma cells. (askhematologist.com)
Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
Furthermore, the infection itself can pathogenetically contribute to the progression of MM through different mechanisms, such as robust production of promyeloma cytokines (e.g., interleukin-6) and activation of Toll-like receptors on malignant plasma cells [ 6 - 10 ]. (jcancer.org)

A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)

MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
Overview of Plasma Cell Disorders Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (merckmanuals.com)
Multiple Myeloma is a malignant proliferation of plasma cells derived from a single clone. (sunzek.com)
The bone lesions of myeloma are caused by the proliferation of tumour cells and the activation of the osteoclasts that destroy the bone. (sunzek.com)

2019. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. . (cornell.edu)
Patients received conditioning with HDT with BEAM, BeEAM, or CBV from 2019 to 2020. (targetedonc.com)

HDT-AHCT is potentially curative for patients with high-risk, chemotherapy-sensitive lymphomas. (targetedonc.com)

During 2003-2014, we identified 26 patients whose hematological malignancies and HEV infection and report- laboratory test results showed HEV replication. (cdc.gov)
Management of HEV characteristics and treatments of patients with hematologic infection in the context of allogeneic stem cell transplanta- malignancies before or within the 6 months after the diag- tion (SCT) has been a matter of controversy ( 5 , 6 ). (cdc.gov)

Oral complications from cancer therapies are commonly of significant morbidity to the patient and may cause disruption of cancer treatment compromising the prognosis and increase health care costs. (pocketdentistry.com)
An interdisciplinary approach, including dental professionals, is required to work in close collaboration with the patient in order to regularly-and by validated outcome measures-evaluate, prevent, and treat oral complications of cancer therapies. (pocketdentistry.com)
I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
We decided to perform cord blood stem cell transplantation (CBSCT) for hematopoietic rescue after the myeloablative therapies. (biomedcentral.com)
One of the main therapies used for MM is the small-molecule alkylating agent melphalan ( 5 - 7 ). (snmjournals.org)

The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)

Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)

This is likely an effect of treatment duration, with the median number of cycles being 27 in the TNE double exposed patients, vs 6 in the single exposure patients. (nyu.edu)
In selected patients with limited-stage, nonbulky HL with early response confirmed by functional imaging, ABVD for six cycles without RT has proved effective and safe. (medscape.com)
Treatment was frequently interrupted and dose adjusted to account for neutropenia and despite a minor response after six cycles (starting M-protein 47 g/L, finishing M-protein 34 g/L), in October 2009, she proceeded with stem cell mobilisation. (bmj.com)

About half of people with light chain deposition disease also have a plasma cell dyscrasia, a spectrum of diseases that includes multiple myeloma, Waldenström's macroglobulinemia, and the monoclonal gammopathy of undetermined significance premalignant stages of these two diseases. (wikipedia.org)
Training CAR T cells to seek and destroy specific proteins on the surface of multiple myeloma cells (and the cells themselves) are an exciting new area of study. (healthtree.org)
Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
A latent class analysis was used to categorise cancer-related symptoms in Chinese patients undergoing treatment for multiple myeloma (MM). (bmj.com)
Researchers from Memorial Sloan Kettering Cancer Center (MSK) in New York City and MD Anderson Cancer Center in Houston, examined if acupuncture could help manage symptom burden of hematopoietic stem cell transplantation (HCT) in patients with multiple myeloma. (curetoday.com)
Patients with multiple myeloma who are undergoing systemic treatment can see improvements from exercise, a recent study shows. (curetoday.com)
Chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. (cancertreatmenttoday.org)
Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)

secondary end points included severity and duration of grade 3 or higher oral/GI toxicities, and time to neutrophil and platelet engraftment. (targetedonc.com)

Anatomy20

Organisms4

Diseases57

Chemicals and Drugs56

Analytical, Diagnostic and Therapeutic Techniques and Equipment88

Psychiatry and Psychology1

Phenomena and Processes25

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science4

Named Groups4

Health Care25

Geographicals1

ASCT38

Regimens7

Cyclophosphamide12

Etoposide2

Peripheral blood stem6

Transplant39

Blood and marrow transplantation3

Marrow31

Survival25

Busulfan1

Outcomes12

Regimen5

Clinical17

Progenitor cell transplantation1

Myeloma patients6

Relapse7

Acute myelogen3

Dexamethasone2

Induction6

Efficacy4

Post-transplantation4

Graft‐versu1

Radiotherapy1

Lymphoma9

Immunotherapy3

Refractory2

Combination7

Malignancy2

Tumor3

HSCT2

Therapy24

Toxicity4

Neoadjuvant chemotherapy1

Remission3

Tandem2

Newly3

Malignant plasma cells3

Rituximab1

Proliferation5

20192

Lymphomas1

Malignancies2

Therapies5

Immunology1

Salvage1

Cycles3

Multiple8

Neutrophil1